GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curis Inc (NAS:CRIS) » Definitions » 5-Year EBITDA Growth Rate

Curis (CRIS) 5-Year EBITDA Growth Rate : 12.80% (As of Sep. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Curis 5-Year EBITDA Growth Rate?

Curis's EBITDA per Share for the three months ended in Sep. 2024 was $-1.77.

During the past 3 years, the average EBITDA Per Share Growth Rate was 5.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 12.80% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 9.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Curis was 49.00% per year. The lowest was -62.20% per year. And the median was 12.45% per year.

Competitive Comparison of Curis's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Curis's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curis's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curis's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Curis's 5-Year EBITDA Growth Rate falls into.


Curis 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Curis  (NAS:CRIS) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Curis 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Curis's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Curis Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curis Inc (NAS:CRIS) » Definitions » 5-Year EBITDA Growth Rate
Comparable Companies
MLEC CARM PMN NXTC GRCE LTRN ESLA ICCC CERO TNXP VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
CUS0:Germany CUS0:Germany
Address
128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Website
https://www.curis.com
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Executives
Jonathan B. Zung officer: CDO C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Anne Elizabeth Borgman director 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
John Hohneker director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Marc Rubin director C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Kenneth I Kaitin director C/O TUFTS CNTR FOR THE STUDY OF DRUG DEV, 75 KNEELAND ST, SUITE 1100, BOSTON MA 02111
Martyn D Greenacre director 41 MOORES ROAD, FRAZER PA 19355
Robert Martell officer: Head of Research & Development 4 MAGUIRE ROAD, LEXINGTON MA 02421
Diantha Duvall officer: CFO C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James E Dentzer director, officer: President & CEO C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
William Steinkrauss officer: VP, Finance & Treasurer, other: Principal Accounting Officer C/O CURIS, INC.,, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Lori Anne Kunkel director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Fattaey Ali Ph.d. officer: President & COO C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
James R Mcnab director C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Aurigene Discovery Technologies Ltd 10 percent owner 39-40 KIADB INDUSTRIAL AREA, PHASE II, ELECTRONIC CITY HOSUR ROAD, BANGALORE (KARNATAKA) K7 560100
David Tuck officer: Sr. Vice-President C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421